NJ High Court Won’t Disturb Novartis Bone Drug Win

As seen in this Law360 article, “The New Jersey Supreme Court has declined to hear a challenge to judgments for Novartis Pharmaceuticals Corp. in the first bellwether trial in consolidated litigation over claims the drugmaker’s bone cancer drugs Aredia and Zometa caused jaw deterioration.”  The article also states “Novartis is represented by Joe G. Hollingsworth, Katharine R. Latimer, Rebecca A. Womeldorf and Neil S. Bromberg of Hollingsworth LLP and Beth S. Rose of Sills Cummis & Gross P.C.”